• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

螺内酯治疗中心性浆液性脉络膜视网膜病变:一个激发-再激发病例

Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.

作者信息

Ryan Edwin H, Pulido Christine M

机构信息

VitreoRetinal Surgery, PA, Edina, Minnesota.

出版信息

Retin Cases Brief Rep. 2015 Summer;9(3):235-8. doi: 10.1097/ICB.0000000000000147.

DOI:10.1097/ICB.0000000000000147
PMID:25790318
Abstract

PURPOSE

To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern.

METHODS

At presentation, fundus photography, fluorescein angiography, spectral domain optical coherence tomography, and enhanced depth imaging ocular coherence tomography were performed in both eyes. The patient was prescribed 25 mg spironolactone daily along with serum potassium monitoring. At follow-ups, spectral domain optical coherence tomography and enhanced depth imaging ocular coherence tomography were performed.

RESULTS

A 37-year-old white male accountant presenting with CSC. Spironolactone treatment resolved the CSC. After the patient discontinued treatment, it returned. After returning to daily treatment, the CSC again resolved.

CONCLUSION

Spironolactone was an effective treatment of CSC in this case. Other groups have reported similar findings with eplerenone, a similar drug.

摘要

目的

介绍一例采用螺内酯以激发-再激发模式治疗中心性浆液性脉络膜视网膜病变(CSC)的病例。

方法

初诊时,对双眼进行了眼底照相、荧光素血管造影、光谱域光学相干断层扫描和增强深度成像光学相干断层扫描。患者每日服用25毫克螺内酯,并监测血清钾。随访时,进行了光谱域光学相干断层扫描和增强深度成像光学相干断层扫描。

结果

一名37岁的白人男性会计师患有CSC。螺内酯治疗使CSC得到缓解。患者停药后,病情复发。恢复每日治疗后,CSC再次缓解。

结论

在该病例中,螺内酯是治疗CSC的有效药物。其他研究组报道了使用依普利酮(一种类似药物)时的类似发现。

相似文献

1
Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.螺内酯治疗中心性浆液性脉络膜视网膜病变:一个激发-再激发病例
Retin Cases Brief Rep. 2015 Summer;9(3):235-8. doi: 10.1097/ICB.0000000000000147.
2
SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.螺内酯作为中心性浆液性脉络膜视网膜病变囊泡型的治疗选择。
Retin Cases Brief Rep. 2020 Fall;14(4):381-385. doi: 10.1097/ICB.0000000000000719.
3
Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.依普利酮治疗慢性中心性浆液性脉络膜视网膜病变的临床经验。
Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2151-2157. doi: 10.1007/s00417-016-3373-3. Epub 2016 May 5.
4
The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.依普利酮在治疗抵抗性慢性中心性浆液性脉络膜视网膜病变中的应用。
Acta Ophthalmol. 2014 Sep;92(6):e488-90. doi: 10.1111/aos.12392. Epub 2014 Apr 2.
5
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.抗醛固酮受体拮抗剂治疗未缓解中心性浆液性脉络膜视网膜病变的反应预测因素。
Am J Ophthalmol. 2019 Feb;198:80-87. doi: 10.1016/j.ajo.2018.09.034. Epub 2018 Oct 9.
6
Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.醛固酮受体拮抗剂治疗慢性中心性浆液性脉络膜视网膜病变:一项初步研究。
Retina. 2013 Nov-Dec;33(10):2096-102. doi: 10.1097/IAE.0b013e318297a07a.
7
Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.口服依普利酮治疗慢性中心性浆液性脉络膜视网膜病变:病例系列
Ophthalmic Surg Lasers Imaging Retina. 2015 Apr;46(4):439-44. doi: 10.3928/23258160-20150422-06.
8
Eplerenone in patients with chronic recurring central serous chorioretinopathy.依普利酮用于慢性复发性中心性浆液性脉络膜视网膜病变患者。
Eur J Ophthalmol. 2016 Aug 4;26(5):479-84. doi: 10.5301/ejo.5000727. Epub 2015 Dec 17.
9
Spironolactone in the treatment of central serous chorioretinopathy - a case series.螺内酯治疗中心性浆液性脉络膜视网膜病变——病例系列
Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1985-91. doi: 10.1007/s00417-014-2780-6. Epub 2014 Aug 20.
10
SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.螺内酯治疗非消退型中心性浆液性脉络膜视网膜病变:一项随机对照交叉研究
Retina. 2015 Dec;35(12):2505-15. doi: 10.1097/IAE.0000000000000614.

引用本文的文献

1
Oral medications for central serous chorioretinopathy: a literature review.口服药物治疗中心性浆液性脉络膜视网膜病变:文献综述。
Eye (Lond). 2020 May;34(5):809-824. doi: 10.1038/s41433-019-0568-y. Epub 2019 Sep 16.
2
Spironolactone for Secondary Central Serous Chorioretinopathy: A Challenge-Rechallenge Case.螺内酯治疗继发性中心性浆液性脉络膜视网膜病变:一个激发-再激发病例
Case Rep Ophthalmol. 2017 Jul 13;8(2):370-374. doi: 10.1159/000477757. eCollection 2017 May-Aug.